{"nctId":"NCT01605136","briefTitle":"Phase III Confirmatory Study in Erythropoietic Protoporphyria","startDateStruct":{"date":"2012-05"},"conditions":["Erythropoietic Protoporphyria"],"count":93,"armGroups":[{"label":"Afamelanotide","type":"EXPERIMENTAL","interventionNames":["Drug: Afamelanotide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Afamelanotide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects with characteristic symptoms of EPP phototoxicity and a biochemically-confirmed diagnosis of EPP.\n* Aged 18 years old and above (inclusive).\n* Able to understand and sign the written Informed Consent Form.\n* Willing to take precautions to prevent pregnancy until completion of the study (Day 180).\n\nExclusion Criteria:\n\n* Any allergy to afamelanotide or the polymer contained in the implant or to lidocaine or other local anesthetic to be used during the administration of the study medication\n* EPP patients with significant hepatic involvement\n* Personal history of melanoma or dysplastic nevus syndrome.\n* Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions.\n* Any other photodermatosis such as polymorphic light eruption, actinic prurigo, discoid lupus erythematosus, chronic actinic dermatitis or solar urticaria.\n* Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations.\n* Acute history of drug or alcohol abuse (in the last 6 months).\n* Patient assessed as not suitable for the study in the opinion of the Investigator (e.g. noncompliance history, allergic to local anesthetics, faints when given injections or giving blood).\n* Participation in a clinical trial for an investigational agent within 30 days prior to the screening visit.\n* Prior and concomitant therapy with medications which may interfere with the objectives of the study, including drugs that cause photosensitivity or skin pigmentation.\n* Female who is pregnant (confirmed by positive serum Î²-HCG pregnancy test prior to baseline) or lactating.\n* Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0).","description":"The amount of direct sunlight exposure between 10:00 and 18:00 hours on days when no pain was experienced (e.g.11-point Likert pain score of 0). Time was recorded in a patient diary using 15 minute time blocks.\n\nThe pain score is measured by the 11-point Likert Pain scale with minimum of 0 and maximum of 10.\n\nLikert Pain scale of 0 represents no pain and 10 represents worst imaginable pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Combined Sun Exposure and Phototoxic Pain","description":"Time in direct sunlight exposure between 10:00 and 18:00 hours on days when no or mild pain was experienced (Likert scores of 0 to 3).\n\nThe pain score is measured by the 11-point Likert Pain scale with minimum of 0 and maximum of 10.\n\nLikert Pain scale of 0 represents no pain and 10 represents worst imaginable pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"51.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Sun Exposure","description":"Duration of direct sunlight exposure between 10:00 and 18:00 hours during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.50","spread":null},{"groupId":"OG001","value":"65.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Score","description":"The Quality of life of participant is measured using DLQI and EPP QoL. The Dermatology Life Quality Index (DLQI) is a simple practical measure for routine clinical use.\n\nThe DLQI ranges from 0 (no impact on life) to 30 (significant impact on life) . The Erthropoietic protoporphyria quality of life measure (EPP-QoL) scores range from 0 (worst imaginable QoL) to 100 (best possible QoL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null},{"groupId":"OG001","value":"69.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Photoprovocation","description":"A subset of subjects was photoprovoked on the dorsal surface of the hand (predilection place) and lower back and the minimum symptom dose (MSD) determined on Days 0, 30, 60, 90 and 120.\n\nThe amount of radiation required to provoke the first clinical symptom was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"21.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197.5","spread":null},{"groupId":"OG001","value":"75.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.3","spread":null},{"groupId":"OG001","value":"36.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"208.3","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162.1","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"237.1","spread":null},{"groupId":"OG001","value":"44.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227.5","spread":null},{"groupId":"OG001","value":"-2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Severity of Phototoxic Reaction Experienced by Participants","description":"The phototoxicity - phototoxic pain secondary endpoint has been divided into two secondary outcome measures.\n\nThe days on which the participant experienced pain as a result of phototoxic reactions (caused by exposure to natural light) was recorded in a study diary. On each day such a reaction occurred, the participant scored the level of pain using an 11-point Likert pain scale, with minimum of 0 and maximum of 10. The 11-point Likert pain scale with a value of 0 represents no pain and 10 represents worst imaginable pain.\n\nThe maximum severity of a phototoxic reaction was determined by the highest daily 11-point Likert scale score that occurred during that phototoxic reaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number Phototoxic Reactions Experienced by Participants","description":"The phototoxicity - phototoxic pain secondary endpoint has been divided into two secondary outcome measures.\n\nThe number of episodes was the endpoint. The days on which the participant experienced pain as a result of phototoxic reactions (caused by exposure to natural light) was recorded in a study diary. On each day such a reaction occurred, the participant scored the level of pain using an 11-point Likert pain scale, with minimum of 0 and maximum of 10. The 11-point Likert Pain scale with a value of 0 represents no pain and 10 represents worst imaginable pain.\n\nThe number of phototoxic reactions was determined by counting the number of episodes on which participants report a 11-point Likert scale score of 4 or more for one or more consecutive days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":48},"commonTop":["Headache","Nausea","Nasopharyngitis","Back Pain","Implant site discolouration"]}}}